RMD
ResMed Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · US
$228.35
−0.37%Aug 17, 2026, 20:10 UTC
Resmed announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor, who will retire after the 2026 Annual Meeting of Stockholders on November 18, 2026.
Source:Aug 7, 2026, 16:01 UTC
ResMed shares fell about 6% in morning trading on Friday after the company issued a weak fiscal 2027 revenue forecast.
Source:Aug 6, 2026, 21:58 UTC
ResMed reported Q2 CY2026 revenue of $1.46 billion, up 8.6% year on year, in line with analyst estimates, and adjusted EPS of $2.95, beating consensus by 2%.
Aug 6, 2026, 20:21 UTC
ResMed's board of directors declared a quarterly cash dividend of US$0.66 per share, a 10% increase over the previous dividend, with a record date of August 20, 2026, and payable on September 24, 2026.
Jul 10, 2026, 17:56 UTC
Resmed divests its MatrixCare business to an unnamed buyer to sharpen focus on connected care.
Source:Jul 7, 2026, 20:30 UTC
Resmed announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners.
Jun 1, 2026, 20:05 UTC
Resmed completed the acquisition of Noctrix Health, adding Nidra Tonic Motor Activation Therapy to its sleep health portfolio.